Eric Jonasch
M.D. Anderson Cancer Center · ejonasch@mdanderson.org
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Eric Jonasch as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 19:09 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07401875 · A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)M.D. Anderson Cancer Center · recruiting · Phase 1b, HC-7366, SHARK · principal investigator
- Ph2NCT07187778 · Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)M.D. Anderson Cancer Center · recruiting · Clear Cell Renal Cell Carcinoma · principal investigator
- Ph2NCT07023432 · Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)M.D. Anderson Cancer Center · recruiting · Active Surveillance, Clear Cell Renal Cell Carcinoma · principal investigator
- Ph2NCT07011849 · Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain MetastasesM.D. Anderson Cancer Center · withdrawn · Renal Cell Carcinoma, Brain Metastasis · principal investigator
- Ph2NCT06708949 · A Randomized Phase 2 Trial of Nivolumab, Relatlimab Plus Ipilimumab vs. Nivolumab Plus Ipilimumab in First-line Advanced Renal Cell Carcinoma (RCC)M.D. Anderson Cancer Center · active not recruiting · Renal Cell Carcinoma, Clear Cell · principal investigator
- Ph2NCT06284564 · A Phase II Study Bolstering Outcomes by Optimizing Immunotherapy Strategies With Evolocumab and Nivolumab in Patients With Metastatic Renal Cell Carcinoma (BOOST-RCC)M.D. Anderson Cancer Center · active not recruiting · Metastatic Renal Cell Carcinoma · principal investigator
- Ph2NCT06053658 · Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell CarcinomaM.D. Anderson Cancer Center · recruiting · Renal Cell Carcinoma · principal investigator
- N/ANCT05955014 · Data Collection Protocol for Patients With Von Hippel Lindau DiseaseM.D. Anderson Cancer Center · recruiting · Von Hippel Lindau Disease · principal investigator
- Ph1/Ph2NCT05663710 · Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCCM.D. Anderson Cancer Center · recruiting · Advanced Cancer, Clear Cell Renal Cell Carcinoma · principal investigator
- Ph1/Ph2NCT05501054 · Phase 1b/2 Trial of Ipilimumab, Nivolumab, and Ciforadenant (Adenosine A2a Receptor Antagonist) in First-line Advanced Renal Cell Carcinoma.M.D. Anderson Cancer Center · active not recruiting · Renal Cell Carcinoma · principal investigator
- Ph2NCT02060370 · Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC)M.D. Anderson Cancer Center · completed · Genitourinary Cancer, Kidney Cancer · principal investigator
- Ph2NCT01775930 · Carfilzomib in Refractory Renal Cell Carcinoma (RCC)M.D. Anderson Cancer Center · completed · Kidney Cancer · principal investigator
- Ph2NCT01436227 · Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau SyndromeM.D. Anderson Cancer Center · completed · Von Hippel-Lindau Syndrome · principal investigator
- Ph2NCT01266070 · TKI 258 in Von Hippel-Lindau Syndrome (VHL)M.D. Anderson Cancer Center · terminated · Von Hippel-Lindau Syndrome · principal investigator
- Ph2NCT01239342 · Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney CancerNational Cancer Institute (NCI) · terminated · Metastatic Kidney Carcinoma, Recurrent Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7 · principal investigator
- Ph2NCT00918775 · Follow-up After Metastasectomy in Patients With Kidney CancerM.D. Anderson Cancer Center · active not recruiting · Renal Cell Carcinoma · principal investigator
- Ph2NCT00715442 · Pre-Surgical Sutent in Renal Cell Carcinoma (RCC)M.D. Anderson Cancer Center · active not recruiting · Renal Cell Carcinoma · principal investigator
- Ph2NCT00330564 · Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to FollowM.D. Anderson Cancer Center · terminated · Von Hippel-Lindau Syndrome, Renal Cell Carcinoma, Hemangioblastoma · principal investigator
- Ph2NCT00126594 · Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney CancerNational Cancer Institute (NCI) · completed · Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer · principal investigator
- Ph2NCT00126659 · Sorafenib in Treating Patients Who Are Undergoing Surgery for Metastatic Kidney CancerNational Cancer Institute (NCI) · terminated · Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer · principal investigator
- Ph2NCT00113217 · Neoadjuvant Clinical Trial to Evaluate the Efficacy of Bevacizumab for Renal Cell CarcinomaM.D. Anderson Cancer Center · completed · Renal Cell Carcinoma, Kidney Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 19:09 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Biannual von Hippel Lindau Family Alliance Medical MeetingR13CA165693 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2011 · $8,000 awarded in 2011Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Experimental Medicine ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI FUNDA MERIC-BERNSTAM · fiscal years 2013 to 2026
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 19:09 UTC. The ranking covers the 200 most relevant of 55 PubMed records, and a shared surname and initials can bring in a namesake. All 55 on PubMed
- Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease.N Engl J Med · 2021615 citationsRCR 33.5
- 304 citationsRCR 9.8
- Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis.Nat Med · 2021257 citationsRCR 13.7
- Axitinib with or without dose titration for first-line metastatic renal-cell carcinoma: a randomised double-blind phase 2 trial.Lancet Oncol · 2013186 citationsRCR 5.1
- Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma.J Clin Oncol · 2009158 citationsRCR 3.8
- Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.J Clin Oncol · 2017158 citationsRCR 4.8
- Definitive radiotherapy in lieu of systemic therapy for oligometastatic renal cell carcinoma: a single-arm, single-centre, feasibility, phase 2 trial.Lancet Oncol · 2021154 citationsRCR 8.5
- A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma.Eur Urol · 2012145 citationsRCR 3.6
- Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling.PLoS One · 2012123 citationsRCR 3.9
- 118 citationsRCR 2.5